Targeted Thyroid Screening in Patients With Vitiligo: A Practical Narrative Review

Vitiligo is a chronic immune-mediated depigmenting disorder that is strongly associated with autoimmune thyroid disease, the most common autoimmune comorbidity reported in affected patients. Although thyroid abnormalities occur more frequently in patients with vitiligo than in the general population, recommendations regarding routine thyroid screening remain variable. Increasing evidence suggests that thyroid disease risk is not uniform across all patients with vitiligo and may be influenced by specific clinical and phenotypic characteristics. This narrative review examines the epidemiology, temporal relationship, clinical predictors, and proposed pathogenic mechanisms linking vitiligo and thyroid disease, with a focus on practical screening considerations. Current evidence suggests that several clinical and phenotypic features are associated with an increased risk of thyroid dysfunction and autoimmune thyroid disease in patients with vitiligo, including nonsegmental vitiligo, acral involvement, female sex, extensive or progressive disease, longer disease duration, family history of thyroid disease or autoimmunity, the presence of additional autoimmune disorders, and symptoms suggestive of thyroid dysfunction. Thyroid autoantibody positivity is among the most frequently reported markers of thyroid autoimmunity, while subclinical hypothyroidism is among the most common forms of thyroid dysfunction in patients with vitiligo. Thyroid disease may precede or follow the onset of vitiligo, highlighting the importance of ongoing clinical awareness and individualized risk assessment. A targeted, phenotype-guided approach to screening may improve diagnostic yield while reducing unnecessary testing in lower-risk individuals. Thyroid-stimulating hormone remains the most practical initial screening test, with additional laboratory evaluation guided by clinical presentation and individual risk factors. By integrating clinical phenotype, medical history, family history, symptoms, and physical examination findings into screening decisions, clinicians may be better positioned to identify patients most likely to benefit from thyroid evaluation and longitudinal follow-up while avoiding unnecessary testing. This practical approach may be particularly useful in primary care and dermatology settings.